Skip Navigation LinksHome > June 2014 - Volume 37 - Issue 3 > Metastatic Hormone Refractory Prostate Cancer: Recent Advanc...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e318248dc1e
Review Articles

Metastatic Hormone Refractory Prostate Cancer: Recent Advances in Standard Treatment Paradigm, and Future Directions

Keizman, Daniel MD; Maimon, Natalie MD; Gottfried, Maya MD

Collapse Box


Until recently, docetaxel-based chemotherapy was the only established treatment for patients with metastatic hormone refractory prostate cancer (mHRPC). In 2010 to 2011, 3 more agents were shown to be associated with a survival benefit in mHRPC, including the dendritic cell vaccine sipuleucel-T, the 17,20 lyase inhibitor abiraterone, and the taxane cabazitaxel. The improved understanding of prostate cancer biology in recent years led to the development of drugs directed against precise tumorigenesis-associated molecular pathways. Molecular pathways involved in the progression of mHRPC include the androgen receptor, angiogenesis, endothelin receptor, tyrosine kinases (SRC, MET, vascular endothelial growth factor receptor, RET), and the receptor activator of nuclear factor-kB-ligand. This review will focus on recent advances in the standard treatments paradigm, and promising new targeted agents that are being investigated, in mHRPC.

© 2014 by Lippincott Williams & Wilkins, Inc


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.